The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older
Abstract
Although the individual components of the metabolic syndrome are clearly associated with increased risk for coronary heart disease (CHD), we wanted to quantify the increased prevalence of CHD among people with metabolic syndrome. The Third National Health and Nutrition Examination Survey (NHANES III) was used to categorize adults over 50 years of age by presence of metabolic syndrome (National Cholesterol Education Program [NCEP] definition) with or without diabetes. Demographic and risk factor information was determined for each group, as well as the proportion of each group meeting specific criteria for metabolic syndrome. The prevalence of CHD for each group was then determined. Metabolic syndrome is very common, with ∼44% of the U.S. population over 50 years of age meeting the NCEP criteria. In contrast, diabetes without metabolic syndrome is uncommon (13% of those with diabetes). Older Americans over 50 years of age without metabolic syndrome regardless of diabetes status had the lowest CHD prevalence (8.7% without diabetes, 7.5% with diabetes). Compared with those with metabolic syndrome, people with diabetes without metabolic syndrome did not have an increase in CHD prevalence. Those with metabolic syndrome without diabetes had higher CHD prevalence (13.9%), and those with both metabolic syndrome and diabetes had the highest prevalence of CHD (19.2%) compared with those with neither. Metabolic syndrome was a significant univariate predictor of prevalent CHD (OR 2.07, 95% CI 1.66–2.59). However, blood pressure, HDL cholesterol, and diabetes, but not presence of metabolic syndrome, were significant multivariate predictors of prevalent CHD. The prevalence of CHD markedly increased with the presence of metabolic syndrome. Among people with diabetes, the prevalence of metabolic syndrome was very high, and those with diabetes and metabolic syndrome had the highest prevalence of CHD. Among all individuals with diabetes, prevalence of CHD was increased compared with those with metabolic syndrome without diabetes. However, individuals with diabetes without metabolic syndrome had no greater prevalence of CHD compared with those with neither.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In individuals with diabetes, the coexistence of other metabolic syndrome factors denotes a higher risk for future development of ASCVD.69”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [69]
In the citing paper
“the combination of MS and hypertension has been reported to result in an even higher morbidity and mortality.11”
From Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension (2004) · cites this paper as [11]
In the citing paper
“It is already known that MS or EHT patients have a high cardiovascular risk”
From Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension (2004) · cites this paper as [11]
In the citing paper
“ASCVD risk is higher with MetS in the absence of T2D compared with T2D without MetS (13.9% vs. 7.5%, respectively) (13).”
From The CardioMetabolic Health Alliance (2015) · cites this paper as [13]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Cardiovascular Survey Methods.
Rose, G., & Blackburn, H. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1335_2 · Cited by 3,090
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,366
Self-citationGlucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome
Ferrannini, E., Haffner, S. M., Mitchell, B. D., & Stern, M. P. (1991) · Diabetologia · doi:10.1007/bf00403180 · Cited by 898
Self-citationThe homeostasis model in the San Antonio Heart Study.
Haffner, S. M., Miettinen, H., & Stern, M. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1087 · Cited by 788
Self-citationDiagnosing Insulin Resistance in the General Population
McAuley, K. A., Williams, S., Mann, J. I., Walker, R. J., Lewis‐Barned, N., Temple, L. A., & Duncan, A. W. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.460 · Cited by 752
Balkau, B., Shipley, M. J., Jarrett, R. J., Pyörälà, K., Pyörälä, M., Forhan, A., & Eschwège, É. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 597
Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study
Meigs, J. B., D’Agostino, R. B., Wilson, P. W. F., Cupples, L. A., Nathan, D. M., & Singer, D. E. (1997) · Diabetes · doi:10.2337/diacare.46.10.1594 · Cited by 525
Lamarche, B. (1998) · JAMA · doi:10.1001/jama.279.24.1955 · Cited by 418
Meigs, J. B., Nathan, D. M., Wilson, P. W. F., Cupples, L. A., & Singer, D. E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00002 · Cited by 193
Alexander, C. M., Landsman, P. B., & Teutsch, S. M. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01118-8 · Cited by 131
Self-citationAssociazione di iperlipemia, diabete mellito e obesita' di medio grado
AVOGARO, P., Crepaldi, G., Enzi, G., & Tiengo, A. (1967) · Acta Diabetologica · doi:10.1007/bf01544100 · Cited by 106
Hyperinsulinemia and Atherosclerosis
Stout, R. W. (1996) · Diabetes · doi:10.2337/diab.45.3.s45 · Cited by 95
Is glucose a continuous risk factor for cardiovascular mortality?
Gerstein, H. C. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.659 · Cited by 60
Impaired glucose tolerance is it relevant for cardiovascular disease?
Haffner, S. M. (1997) · Diabetologia · doi:10.1007/s001250051430 · Cited by 18
Self-citationHemodynamic and neural effects of urapidil and prazosin in essential hypertensives.
Grassi, G. M., Seravalle, G., Mancia, G., & Zanchetti, A. (1994) · PubMed · Cited by 5
Grobler, T. (1992) · Southern African Journal of Child and Adolescent Mental Health · doi:10.1080/16826108.1992.9631476 · Cited by 1
Cited by
Sorted by citations
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
“doubling of CVD risk when the MetS is present (377, 390).”
BackgroundGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Metadata
- Authors
- Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- The University of Texas at San Antonio Health Science Center (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2003-05-01
- Volume
- 52
- Issue
- 5
- Pages
- 1210-1214
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2151152924
- Cited by
- 1,475
- References
- 30
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 30 · 2021: 37 · 2020: 32 · 2019: 30 · 2018: 42 · 2017: 39 · 2016: 51 · 2015: 43 · 2014: 61 · 2013: 65 · 2012: 73
- FWCI
- 77.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- metabolic syndrome, coronary artery disease, prevalence, older adults, NCEP criteria, NHANES III, cardiovascular risk factors, blood pressure, HDL cholesterol
- MeSH terms
- Age Factors, Blood Pressure, Body Constitution, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Patient Education as Topic, Physical Examination, Surveys and Questionnaires, Risk Factors, Smoking, United States, Prevalence, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review